Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01207752 · ClinicalTrials.gov registry record · NA

The Efficacy of an Ocular Emulsion in Meibomian Gland Dysfunction

A NA study of Meibomian Gland Dysfunction, sponsored by Southern California College of Optometry at Marshall B. Ketchum University.

Completed
Registry status
NA
Development phase
69
Enrollment target
1
Study location

NCT01207752 is a NA study of Meibomian Gland Dysfunction that has completed, run by Southern California College of Optometry at Marshall B. Ketchum University. The registered enrollment target is 69 participants, below the 94-participant average among 8 other Meibomian Gland Dysfunction trials with a reported enrollment target (27% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01207752, a NA study of Meibomian Gland Dysfunction, has completed, sponsored by Southern California College of Optometry at Marshall B. Ketchum University.

COMPLETED
Registry status
NA
Development phase
69 participants
Enrollment target
1
Study location

Study Summary

The aim of this study will be to determine the efficacy of this novel, lipid-containing artificial tear on the signs and symptoms of meibomian gland disease.

Interventions

  • DRUG Systane Balance
  • DRUG Optive Lubricant Eye Drops

Study Locations (1)

California

  • Eye Care Center - Fullerton

Trial Details

FieldValue
Enrollment Target 69 participants
Start Date 2010-09
Est. Completion 2011-07
Phase NA

What the Registry Record Tells You About NCT01207752

The ClinicalTrials.gov registry entry for NCT01207752 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 94-participant average among 8 other Meibomian Gland Dysfunction trials with a reported enrollment target (27% lower). The listed sponsor is Southern California College of Optometry at Marshall B. Ketchum University, which has 18 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Meibomian Gland Dysfunction appearing as the primary indexed condition, and to 2 interventions - of which Systane Balance is the first listed.

NCT01207752 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT01207752 about?

NCT01207752 is a clinical study titled "The Efficacy of an Ocular Emulsion in Meibomian Gland Dysfunction". The aim of this study will be to determine the efficacy of this novel, lipid-containing artificial tear on the signs and symptoms of meibomian gland disease.

What is the current status of trial NCT01207752?

This trial is currently completed. It is a NA study. The enrollment target is 69 participants. The study started on 2010-09. Estimated completion is 2011-07.

What conditions does trial NCT01207752 study?

This clinical trial studies the following conditions: Meibomian Gland Dysfunction.

What interventions are being tested in trial NCT01207752?

The interventions under investigation include: Systane Balance (DRUG), Optive Lubricant Eye Drops (DRUG).

Who is sponsoring clinical trial NCT01207752?

This trial is sponsored by Southern California College of Optometry at Marshall B. Ketchum University, which has 18 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01207752 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Meibomian Gland Dysfunction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.